Search Results - "Laribi, Kamel"

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study by Raje, Noopur, Terpos, Evangelos, Willenbacher, Wolfgang, Shimizu, Kazuyuki, García-Sanz, Ramón, Durie, Brian, Legieć, Wojciech, Krejčí, Marta, Laribi, Kamel, Zhu, Li, Cheng, Paul, Warner, Douglas, Roodman, G David

“…Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord…”
Get full text

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial by Wei, Andrew H., Montesinos, Pau, Ivanov, Vladimir, DiNardo, Courtney D., Novak, Jan, Laribi, Kamel, Kim, Inho, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Samoilova, Olga, Hu, Yu, Anagnostopoulos, Achilles, Bergeron, Julie, Hou, Jing-Zhou, Murthy, Vidhya, Yamauchi, Takahiro, McDonald, Andrew, Chyla, Brenda, Gopalakrishnan, Sathej, Jiang, Qi, Mendes, Wellington, Hayslip, John, Panayiotidis, Panayiotis

“…Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with…”
Get full text

A revised international prognostic score system for Waldenström’s macroglobulinemia by Kastritis, Efstathios, Morel, Pierre, Duhamel, Alain, Gavriatopoulou, Maria, Kyrtsonis, Marie Christine, Durot, Eric, Symeonidis, Argiris, Laribi, Kamel, Hatjiharissi, Evdoxia, Ysebaert, Loic, Vassou, Amalia, Giannakoulas, Nikolaos, Merlini, Giampaolo, Repousis, Panagiotis, Varettoni, Marzia, Michalis, Euridyki, Hivert, Bénédicte, Michail, Michalis, Katodritou, Eirini, Terpos, Evangelos, Leblond, Veronique, Dimopoulos, Meletios A.

“…A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised…”
Get full text

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM by Jakubowiak, Andrzej, Offidani, Massimo, Pégourie, Brigitte, De La Rubia, Javier, Garderet, Laurent, Laribi, Kamel, Bosi, Alberto, Marasca, Roberto, Laubach, Jacob, Mohrbacher, Ann, Carella, Angelo Michele, Singhal, Anil K., Tsao, L.Claire, Lynch, Mark, Bleickardt, Eric, Jou, Ying-Ming, Robbins, Michael, Palumbo, Antonio

“…In this proof-of-concept, open-label, phase 2 study, patients with relapsed/refractory multiple myeloma (RRMM) received elotuzumab with bortezomib and…”
Get full text

Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review by Laribi, Kamel, Sobh, Mohamad, Ghez, David, Baugier de Materre, Alix

“…The incidence of acute myeloid leukemia increases with age, and more than half of AML patients are over 60 years old. Treating elderly AML patients presents…”
Get full text

Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO) by Laribi, Kamel, Poulain, Stéphanie, Willems, Lise, Merabet, Fatiha, Le Calloch, Ronan, Eveillard, Jean R., Herbaux, Charles, Roos‐Weil, Damien, Chaoui, Driss, Roussel, Xavier, Tricot, Sabine, Dupuis, Jehan, Dartigeas, Caroline, Bareau, Benoit, Bene, Marie C., Baugier de Materre, Alix, Leblond, Véronique

Get full text

Response to vaccination against SARS‐CoV‐2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study by Tomowiak, Cécile, Leblond, Véronique, Laribi, Kamel, Baron, Marine, Puppinck, Christian, Gérard, Paulette, Courret, Elodie, Gorochov, Guy, Sterlin, Delphine, Tournilhac, Olivier, Morel, Pierre, Cymbalista, Florence, Roos‐Weil, Damien

Get full text

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study by Michallet, Anne-Sophie, Aktan, Melih, Hiddemann, Wolfgang, Ilhan, Osman, Johansson, Peter, Laribi, Kamel, Meddeb, Balkis, Moreno, Carol, Raposo, João, Schuh, Anna, Ünal, Ali, Widenius, Tom, Bernhardt, Alf, Kellershohn, Kerstin, Messeri, Dimitri, Osborne, Stuart, Leblond, Véronique

“…MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic…”
Get full text

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO) by Laribi, Kamel, Poulain, Stéphanie, Willems, Lise, Merabet, Fatiha, Herbaux, Charles, Roos-Weil, Damien, Laribi de Materre, Inès, Roussel, Xavier, Nudel, Morgane, Tricot, Sabine, Dupuis, Jehan, Le Calloch, Ronan, Bareau, Benoit, Leblond, Véronique

“…The bendamustine-rituximab (BR) schedule is an efficient first-line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who…”
Get full text

IgM k multiple myeloma with monoclonal surface immunoglobulin expression by Laribi, Kamel, Alani, Mustafa, Lemaire, Pierre

Get full text

Response to vaccination against SARS-CoV-2 in 168 patients with Waldenström macroglobulinemia: a French Innovative Leukemia Organization (FILO) study by Tomowiak, Cécile, Leblond, Véronique, Laribi, Kamel, Baron, Marine, Puppinck, Christian, Gérard, Paulette, Courret, Elodie, Gorochov, Guy, Sterlin, Delphine, Tournilhac, Olivier, Morel, Pierre, Cymbalista, Florence, Roos-Weil, Damien

Get full text

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial by Braun, Thorsten, Itzykson, Raphael, Renneville, Aline, de Renzis, Benoit, Dreyfus, François, Laribi, Kamel, Bouabdallah, Krimo, Vey, Norbert, Toma, Andrea, Recher, Christian, Royer, Bruno, Joly, Bertrand, Vekhoff, Anne, Lafon, Ingrid, Sanhes, Laurence, Meurice, Guillaume, Oréar, Cédric, Preudhomme, Claude, Gardin, Claude, Ades, Lionel, Fontenay, Michaela, Fenaux, Pierre, Droin, Nathalie, Solary, Eric

“…Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and/or myelodysplastic features…”
Get full text

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations by Adès, Lionel, Duployez, Nicolas, Guerci‐Bresler, Agnes, Laribi, Kamel, Peterlin, Pierre, Vey, Norbert, Thepot, Sylvain, Wickenhauser, Stefan, Zerazhi, Hacene, Stamatoullas, Aspassia, Wattel, Eric, Recher, Christian, Toma, Andrea, Dimicoli‐Salazar, Sophie, Braun, Thorsten, Beyne‐Rauzy, Odile, Marolleau, Jean‐Pierre, Cheze, Stéphane, Park, Sophie, Cluzeau, Thomas, Nimubona, Stanislas, Bordessoule, Dominique, Benramdane, Riad, Quesnel, Bruno, Amé, Shanti, Botton, Stéphane, Chermat, Fathia, Preudhomme, Claude, Chevret, Sylvie, Fenaux, Pierre

“…In order to improve the outcome observed with azacitidine (AZA) in higher‐risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be…”
Get full text

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure by Sébert, Marie, Renneville, Aline, Bally, Cécile, Peterlin, Pierre, Beyne-Rauzy, Odile, Legros, Laurence, Gourin, Marie-Pierre, Sanhes, Laurence, Wattel, Eric, Gyan, Emmanuel, Park, Sophie, Stamatoullas, Aspasia, Banos, Anne, Laribi, Kamel, Jueliger, Simone, Bevan, Luke, Chermat, Fatiha, Sapena, Rosa, Nibourel, Olivier, Chaffaut, Cendrine, Chevret, Sylvie, Preudhomme, Claude, Adès, Lionel, Fenaux, Pierre

“…High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel…”
Get full text

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy by Wei, Andrew H., Panayiotidis, Panayiotis, Montesinos, Pau, Laribi, Kamel, Ivanov, Vladimir, Kim, Inho, Novak, Jan, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Bergeron, Julie, Ting, Stephen B., Hou, Jing-Zhou, Anagnostopoulos, Achilles, McDonald, Andrew, Murthy, Vidhya, Yamauchi, Takahiro, Wang, Jianxiang, Chyla, Brenda, Sun, Yan, Jiang, Qi, Mendes, Wellington, Hayslip, John, DiNardo, Courtney D.

“…VIALE-C compared the safety and efficacy of venetoclax or placebo plus low-dose cytarabine (+LDAC) in patients with untreated AML ineligible for intensive…”
Get full text

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study by Ianotto, Jean-Christophe, Chauveau, Aurélie, Boyer-Perrard, Françoise, Gyan, Emmanuel, Laribi, Kamel, Cony-Makhoul, Pascale, Demory, Jean-Loup, de Renzis, Benoit, Dosquet, Christine, Rey, Jerome, Roy, Lydia, Dupriez, Brigitte, Knoops, Laurent, Legros, Laurence, Malou, Mohamed, Hutin, Pascal, Ranta, Dana, Benbrahim, Omar, Ugo, Valérie, Lippert, Eric, Kiladjian, Jean-Jacques

“…We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated…”
Get full text

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial by Guièze, Romain, Ysebaert, Loïc, Roos-Weil, Damien, Fornecker, Luc-Mathieu, Ferrant, Emmanuelle, Molina, Lysiane, Aurran, Thérèse, Clavert, Aline, de Guibert, Sophie, Michallet, Anne-Sophie, Saad, Alain, Drénou, Bernard, Quittet, Philippe, Hivert, Bénédicte, Laribi, Kamel, Gay, Julie, Quinquenel, Anne, Broseus, Julien, Rouille, Valérie, Schwartz, David, Magnin, Benoit, Lazarian, Grégory, Véronèse, Lauren, de Antonio, Marie, Laurent, Camille, Tournilhac, Olivier, Pereira, Bruno, Feugier, Pierre

“…Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19…”
Get full text

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study by Talbot, Alexis, Bobin, Arthur, Tabone, Léa, Lambert, Jérôme, Boccaccio, Catherine, Deal, Cécile, Petillon, Marie-Odile, Allangba, Olivier, Agape, Philippe, Arnautou, Pierre, Belkhir, Rakiba, Cailleres, Sylvie, Chaoui, Driss, Chrétien, Marie-Lorraine, Decaux, Olivier, Schulmann, Samantha, Frenzel, Laurent, Gastaud, Lauris, Huart, Antoine, Hulin, Cyrille, Karlin, Lionel, Laribi, Kamel, Le Calloch, Ronan, Lenain, Pascal, Macro, Margaret, Manier, Salomon, Montes, Lydia, Moreau, Stéphane, Moreau, Philippe, Morel, Véronique, Norwood, James, Piocelle, Frédérique Orsini, Perrot, Aurore, Pica, Gian Matteo, Rey, Philippe, Schmitt, Anna, Stoppa, Anne-Marie, Tiab, Mourad, Touzeau, Cyrille, Vidal, Valérie, Vignon, Marguerite, Vincent, Laure, Van De Wyngaert, Zoé, Zarnitsky, Charles, Kerbouche, Naima, Paka, Prani, Leleu, Xavier, Arnulf, Bertrand, Avet-Loiseau, Hervé

“…Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess…”
Get full text

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study by Comont, Thibault, Meunier, Mathieu, Cherait, Amina, Santana, Clemence, Cluzeau, Thomas, Slama, Bohrane, Laribi, Kamel, Giraud, Jean‐Thomas, Dimicoli, Sophie, Berceanu, Ana, Le Clech, Lenaïg, Cony‐Makhoul, Pascale, Gruson, Berangere, Torregrosa, Jose, Sanhes, Laurence, Jachiet, Vincent, Azerad, Marie‐Agnes, Al Jijakli, Ahmad, Gyan, Emmanuel, Gaudin, Clement, Broner, Jonathan, Guerveno, Claire, Guillaume, Thierry, Ades, Pr Lionel, Beyne‐Rauzy, Odile, Fenaux, Pierre

“…Summary Despite a moderate prevalence in low‐risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains a risk…”
Get full text

Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study by Laribi, Kamel, Badinand, Delphine, Janoray, Philippe, Benabed, Khaled, Mouysset, Jean-Loup, Fabre, Elizabeth, Monchecourt, Françoise, Diab, Rafik

“…Purpose Few studies are currently available among elderly patients, justifying the need for better understanding of daily medical practices in terms of use of…”
Get full text